About Novadiol

About company

Novadiol is a Kansas-based biopharmaceutical company that develops innovative medicines for people with kidney diseases. The company's late-stage candidate, Dendocrin, is focused on chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT). Unlike new chemical entities (NCE’s), Dendocrin has relatively low development risk and low development costs. With a well-known safety and toxicity profile, Dendocrin is being re-positioned for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) stages 3 and 4 patients. Novadiol, Inc was founded in 2012 and Shawnee, KS, USA.